Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL

This is a Prospective Single Center, open label, Non-randomized, Single Arm, Single Dose, Phase II Clinical Trial. Adult patients \>18-year-old with CD19+ Non-Hodgkin lymphoma are eligible for the study if they meet eligibility criteria. Patients will receive a fresh single dose of MB-CART-19.1 and will be followed for 12 months and evaluated for efficacy and safety.

Trial Details

NCT ID
NCT07271121
Phase
PHASE2
Sponsor
King Hussein Cancer Center
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • MB-CART-19.1
Locations (sample)
  • Amman, Jordan|31.95522,35.94503

Key Eligibility Criteria

  • Eligible patients with a diagnosis of aggressive NHL:
  • Patients after progression on at least one standard chemotherapy and one salvage regimen or
  • Patients considered for alloSCT but are found ineligible or
  • Patients who have relapsed post alloSCT at least 100 days post-transplant, with no evidence of active GVHD, and no longer taking immunosuppressive …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →